This company offers a comprehensive suite of preclinical drug discovery services, including target verification, protein and antibody production, and in vitro/in vivo drug testing. They help accelerate the development of small molecule and biologic drugs by providing solutions for pharmacological efficacy and pharmacokinetics.
Funding
Funding not disclosed
Founders
Product
Problem
Drug discovery is a complex and lengthy process, requiring extensive preclinical research to identify and validate drug targets, produce necessary proteins and antibodies, and conduct in vitro and in vivo testing. These early stages are critical for determining pharmacological efficacy and pharmacokinetics but can be resource-intensive and time-consuming.
Solution
BioMetas offers a suite of preclinical drug discovery services designed to accelerate the development of both small molecule and biologic drugs. Their services encompass target verification, ensuring the selected target is relevant and druggable. They also provide protein and antibody production services, delivering high-quality reagents for research and development. Furthermore, BioMetas conducts comprehensive in vitro and in vivo drug testing to assess pharmacological efficacy and understand pharmacokinetic properties, providing crucial data for informed decision-making in drug development.
Target Audience
BioMetas serves pharmaceutical companies, biotechnology firms, and academic research institutions involved in preclinical drug discovery and development.
Features
- Target verification services to validate drug targets.
- Protein and antibody production for research and development purposes.
- In vitro drug testing to assess pharmacological efficacy.
- In vivo drug testing to evaluate pharmacokinetic properties.